Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Next Previous
Trial Profile

A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
  • Indications Endometrial cancer; Gynaecological cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

  • 28 May 2025 Status changed from recruiting to completed.
  • 04 Jun 2024 Results (As of November 09, 2023, n=170) assessing the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced EC presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 13 Sep 2022 Results(As of February 18, 2022, n=29 ) assessing efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer .presented at the 47th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top